|
Manufacturing review: the sample was not returned by the facility for further evaluation.Lot history review revealed there are a total of two (2) complaints for corporate lot number gfbw0340.Both of the complaints are for an allegation for reocclusion, which includes this complaint.A dhr review was conducted and there was nothing found to indicate there was a manufacturing related cause for this event.Investigation summary: the sample was not returned by the facility for further evaluation.It is known that approximately 10 months post index procedure, the target lesion was reportedly reoccluded via dus imaging.A revascularization was performed and the physician deemed it was successful.The investigator assessed that the event was possibly related to the study devices, but not related to the procedure.Label review: based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.
|
|
It was reported through a post market clinical study that during the index procedure, two lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter were used to treat the target lesion located in the right femoral artery.Approximately 10 months after the index procedure, the patient¿s right femoral artery was reportedly reoccluded.A revascularization was performed and the health care professional (hcp) deemed it was successful.The investigator assessed that the event was possibly related to the study device, but not related to the procedure.
|